Nephrocare Health Services Ltd (NEPHROPLUS)
₹702.00
Mkt cap
₹7,009 Cr
P/E ratio
82.40
P/B
6.32
Div yield
0.00%
ROE
8.83%
ROCE
15.30%
EPS (TTM)
₹8.52
Book value
₹111
52W range
449–751
Sector
Healthcare
Price history
Previous close
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets. [1]
NSE NEPHROPLUSBSE 544647
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−6.56% from high₹702
₹449+56.30% from low₹751
Current
₹702.00
Prev close
₹700.00
Day
+0.29%
Price performance
1D
+0.29%
1W
+2.79%
1M
+1.13%
3M
−1.02%
6M
+25.81%
1Y
—
YTD
+47.98%
Financials
Revenue, profit & margin
P/E ratio
82.4×
NEPHROPLUS is 94% above the sector median of 42.5×
NEPHROPLUS82.4×
Sector median42.5×
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|
| Sales | 197 | 219 | 228 | 246 | 260 | 266 | 282 | |
| Expenses | 153 | 168 | 180 | 182 | 199 | 215 | 221 | |
| Operating Profit | 44 | 51 | 48 | 64 | 61 | 51 | 60 | |
| OPM % | 22% | 23% | 21% | 26% | 23% | 19% | 21% | |
| Other Income | 5 | 4 | 7 | 4 | 3 | 12 | 7 | |
| Interest | 5 | 6 | 6 | 45 | 6 | 3 | 2 | |
| Depreciation | 18 | 19 | 20 | 23 | 22 | 26 | 25 | |
| Profit before tax | 26 | 30 | 29 | -1 | 36 | 33 | 41 | |
| Tax % | 24% | 17% | 17% | 1,427% | 11% | 9% | 22% | |
| Net Profit | 20 | 25 | 24 | -9 | 32 | 30 | 32 | |
| EPS in Rs | 96.50 | 119.30 | 13.10 | -5.24 | 3.21 | 3.03 | 3.19 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −4.65% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 11 Aug '26◦ |
| Earnings day | −4.65% |
| +1 day | −5.11% |
| +5 days | −2.99% |
| +15 days | −2.75% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202663.85%Promoter
Promoters63.85%
FIIs8.78%1.16
DIIs9.05%0.41
Public18.30%0.74
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| LALPATHLAB | ₹1,877.50 | 56.05 | 31,514 | 0.75% | 171 | +28.02% | 798 | +19.10% | 28.00% |
| VIJAYA | ₹1,493.20 | 82.03 | 15,380 | 0.13% | 53 | +37.60% | 231 | +22.83% | 20.53% |
| METROPOLIS | ₹588.70 | 58.65 | 12,209 | 0.34% | 57 | +25.77% | 450 | +16.62% | 17.81% |
| THYROCARE | ₹576.15 | 50.74 | 9,170 | 1.62% | 51 | +34.06% | 240 | +24.34% | 35.38% |
| NEPHROPLUS | ₹697.05 | 82.36 | 7,009 | 0.00% | 32 | +34.89% | 282 | +23.69% | 15.34% |
| KRSNAA | ₹560.00 | 18.36 | 1,817 | 0.36% | 16 | −19.12% | 211 | +19.95% | 12.70% |
| SURAKSHA | ₹332.45 | 48.36 | 1,731 | 0.15% | 13 | +38.40% | 88 | +20.75% | 17.29% |
| Median: 15 Co. | ₹542.40 | 42.48 | 1,253 | 0.00% | 14 | +28.77% | 157 | +19.52% | 23.07% |
Filings
Concall transcripts9
Credit ratings3
Announcements5
Disclosure Under Regulation 30 Of The SEBI Listing Regulations - Grant Of Esops Under The Nephroplus Employee Stock Option Scheme 2026. 3 Sep - NRC approved grant of 4,01,362 ESOPs on September 3, 2026 at ₹230 exercise price.Announcement under Regulation 30 (LODR)-Acquisition 1 Sep - NPHSK LLP to acquire 100% of Dialysis Center Almaty LLP for KZT 561.66 million.Disclosure Under Regulation 30 Of SEBI Listing Regulations 31 Aug - Uzbekistan tax department raised ₹14.79 crore assessment and penalty on NCA for 2023-25; company plans appeal.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 19 Aug - Transcripts for the investors Earning call held on August 12, 2026.Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements 17 Aug - Subsidiary acquired dialysis center assets in Abuyog, Leyte, Philippines for PhP 75 million on August 17, 2026.